jRCT1030260018招募中不适用
An observational study on the safety and therapeutic effects of oral administration of Quercefit in subjects with aging symptoms
未提供0 个研究点目标入组 10 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •1.Male or female aged 20 years or older at the time of informed consent.
- •2.Individuals who complain of aging symptoms, such as physical decline or chronic fatigue.
- •3.Individuals who fully understand the study and provide written voluntary informed consent.
排除标准
- •Patients who were unable to continue due to hypersensitivity or allergic reactions to organic germanium.
- •Patients who are taking other drugs concomitantly, or patients who have previously participated in clinical trials and have not yet been on the last dose of the test drug for more than one month.
- •Patients who are otherwise deemed inappropriate by the principal investigator or co-investigator.
研究者
相似试验
招募中
2 期
A study to investigate the safety and clinical activity of belantamab for the treatment of multiple myeloma when used as monotherapy and in combination treatments.Multiple myeloma2022-501941-63-00Glaxosmithkline Research & Development Limited3
招募中
1 期
A clinical study to investigate the safety, tolerability and pharmacokinetic profile of single ascending concentrations of OPT101 in peritoneal dialysis patients.Chronic kidney disease2025-522966-61-00OPTERION Health AG12
招募中
不适用
A Clinical Study of Islatravir/MK-8507 (MK-8591B) in Healthy Japanese ParticipantsHIV infectionjRCT203125065524
招募中
2 期
Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD).2022-501250-12-01Sparingvision17
招募中
1 期
Clinical study to test the safety, tolerance and preliminary efficacy of oral ITF3756 administered alone or in combination with an anti-protein 4 agent associated with cytotoxic T lymphocytes in patients with advanced solid tumors.2022-501089-22-00Italfarmaco S.p.A.60